Skip to main content


Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit

Updates regarding government operating status and resumption of normal operations can be found at

Grant Details

Grant Number: 5R44CA077986-03 Interpret this number
Primary Investigator: Swartz, Lynne
Organization: Oregon Center For Applied Science, Inc.
Project Title: Pharmacological AIDS for Interactive Smoking Cessation
Fiscal Year: 2002
Back to top


DESCRIPTION: Pharmacological aids such as nicotine replacement (NR) products and buproprion (Zyban) have been demonstrated to be efficacious under FDA-specified conditions. However, despite the improved success in stopping smoking associated with using such products, many people either do not use them or do not use them properly. The primary aims of this project are to develop and test a tailored multimedia intervention designed to improve smoking cessation success by: a) motivating cigarette smokers to use pharmacological aids such as NR products and Zyban, b) assisting them in choosing the type of pharmacological aid best suited to them, and c) ensuring that they employ optimal technique for the use of the chosen pharmacological aid. In Phase I, a complete NR/Zyban intervention segment tailored for the older, Caucasian, female subpopulation was produced for use with our previously developed interactive multimedia smoking cessation programs. The efficacy of the segment was demonstrated in a randomized-control trial. In Phase II, we will develop pharmacological intervention materials explicitly tailored to the characteristics and needs of eleven other sub-populations (using three dimensions: age, race/ethnicity, and gender). The pharmacological intervention materials developed in Phase II will be disseminated in both kiosk and Internet/intranet formats.

Back to top



Back to Top